All Drug Delivery articles – Page 6
-
NewsEngineers target neurons with modified lipid nanoparticles
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
-
NewsRadiotracer targets key cancer biomarker for precision treatment
A breakthrough in molecular imaging could transform how doctors target solid tumours, offering more personalised and effective treatment options.
-
NewsHalozyme’s €2 billion bid to transform drug discovery
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
-
NewsNew DNA nanostructures set to transform cancer treatment
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
-
NewsBlood-brain barrier breakthrough for ALS and Alzheimer's disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
-
ReportBeyond the lab: antibodies
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
-
ArticleCombining precision bispecific antibodies with targeted radiotherapy
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander ...
-
Article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional ...
-
WebinarOvercoming critical challenges in AI-driven drug discovery
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer ...
-
Article
Part three: 15 pragmatic guidelines to handle data quality issues
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this third article, he discusses pragmatic guidelines to help support better data quality.
-
NewsElucidating the aggregation rules for short peptides
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
-
ArticleAdvancing CAR-T therapy: how CD5 modulation is shaping cancer treatment
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
-
ArticleCombatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
-
ArticleWomen in STEM with Charlotte Owens
As Senior Vice President and Head of Global Medical Affairs & Outcomes Research at the global healthcare company Organon, Charlotte Owen’s extensive work is advancing women’s healthcare and overcoming health inequities.
-
NewsNew two-step vaccination strategy for influenza
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
-
ArticleHow mRNA technology could revolutionise therapeutics
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
-
NewsThe role of KDR in the survival of HTLV-1-infected T cells
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
-
NewsPrime editing corrects the CFTR gene mutation
The approach precisely and durably corrects the CFTR mutation in human lung cells, which could lead to superior treatments.
-
NewsImproving vaccine responses by targeting IL-10
In an animal model, scientists have demonstrated that targeting Interleukin-10 during vaccine delivery enhances the vaccine’s ability to protect against infection.
-
ArticleUnleashing the potential of lab-grown recombinant polyclonal antibodies
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.